<DOC>
	<DOCNO>NCT02796053</DOCNO>
	<brief_summary>Study ass Pharmacodynamics , Safety , Pharmacokinetics clinical effect TAB08 12 week treatment patient Psoriasis Vulgaris , adequately control current therapy .</brief_summary>
	<brief_title>TAB08 Patients With Psoriasis Vulgaris , Not Adequately Controlled With Current Treatment</brief_title>
	<detailed_description>1 . To assess dynamic T-lymphocytes subpopulation patient peripheral blood 12 week TAB08 treatment . 2 . To assess dynamic select cytokine level patient peripheral blood 12 week TAB08 treatment . 3 . To assess TAB08 concentration patient blood 12 week TAB08 treatment . 4 . To assess frequency , seriousness severity adverse event 12 week TAB08 treatment . 5 . To assess change PASI , IGA DLQI 12 week TAB08 treatment subsequent 4 week follow-up .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Confirmed diagnosis Vulgar Psoriasis Area Psoriasis skin damage ≥ 10 % PASI Score ≥ 12 Score IGA scale ≥ 3 Other form psoriasis addition vulgar Prohibited treatment Pregnant nursing woman Concomitant systemic therapy dosage modification ( ) within 4 week randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>